- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
MRI may help doctors predict more aggressive prostate cancer in patients, suggests study
New Corewell Health research suggests an MRI scan can help predict whether patients with intermediate-risk prostate cancer (cancer confined to the entire prostate) may have more aggressive cancer in five years.
Knowing this could potentially help doctors determine if treatment is needed up front vs. using a method called active surveillance where the disease is closely monitored over time. The study, recently published in the Journal of Urology, is the first to evaluate this risk group.
Currently, there has been a growing trend to manage low-risk prostate cancer patients with active surveillance to help patients avoid side effects associated with surgery or radiation. Patients are considered low risk when less than half of one lobe of the prostate is affected, and the cancer cells haven’t mutated or changed much. However, for intermediate-risk patients, choosing what treatment path is best can be a bit more challenging for doctors.
“While active surveillance is the standard of care for low-risk patients, it's been unclear whether patients with a slower-growing form of intermediate-risk prostate cancer should be carefully watched or undergo immediate treatment,” said Kiran Nandalur, M.D., principal investigator of the study and a radiologist at Corewell Health William Beaumont University Hospital. “Our data suggests that an MRI can show suspicious lesions based on size and markers of tumor aggression, which may help doctors differentiate a treatment path for these patients.”
In the study, about 1,500 low- and intermediate-risk patients across Michigan were examined to determine if individuals with suspicious findings on an MRI test returned with a more advanced stage of the disease within five years. Here’s what the study found:
Overall, 36% of the study participants who were watching their prostate cancer demonstrated more aggressive disease within five years.
Considering traditional risk factors and using an MRI classification system that rates lesion suspicion, patients with high-risk imaging features were approximately 130% more likely to have more aggressive disease on follow-up than those with low-risk imaging results.
Suspicious lesions on an MRI indicated more than twice the risk of progressive disease in both low-risk and intermediate-risk prostate cancer patients, which has not been previously shown in the intermediate-risk patients.
“The implication for patients and doctors is that an upfront MRI is important before undertaking any active surveillance for prostate cancer since it may help predict if an individual might come back with worse disease later,” Dr. Nandalur said. “This type of imaging helps pave the way for treatment planning so patients can live their lives to the fullest whether they decide to watch their cancer or seek treatment.”
Additional institutions contributing to the study include the Department of Urology at Wayne State University in Detroit, Michigan; Michigan Institute of Urology in West Bloomfield, Michigan; Brady Urologic Institute at Johns Hopkins University in Baltimore, Maryland; and the Michigan Urological Surgery Improvement Collaborative.
References: Kiran R. Nandalur, Chen Shen, Lil Zhao, Sayf Al-Katib, Joseph Lee, Brian Seifman, Hong Ye, Kevin Ginsburg, Thomas Quinn, Sirisha Nandalur, Arvin George, David Gangwish, Abhay Dhaliwal, Connor Erwin, Amanda Young, Akram Albeer, and Jason Hafron https://doi.org/10.1097/JU.0000000000004117
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751